Specifically, curcumin downregulated the p210 BCR‐ABL fusion protein—a hallmark of CML—and suppressed downstream signaling proteins such as MEK‐1 and c‐JUN, effectively impairing leukemic cell survival. This evidence concerns the gene MAP2K1 and chronic myelogenous leukemia, BCR-ABL1 positive.